Last reviewed · How we verify

NCT05585463: ACUSAFE2021

Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)

Completed Last updated 20 October 2022
What this trial tests

trial testing acupuncture in Cancer Pediatric in 460 participants. Completed in 31 October 2021.

Timeline
1 September 2019
Primary endpoint
30 September 2021
31 October 2021

Quick facts

Lead sponsorFundació Sant Joan de Déu
StatusCompleted
Study typeOBSERVATIONAL
Enrollment460
Start date1 September 2019
Primary completion30 September 2021
Estimated completion31 October 2021
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Fundació Sant Joan de Déu — full company profile →

Who can join

Adults 1 Day to 34, any sex, with Cancer Pediatric or Neutropenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to demonstrate the safety of intracutaneous needles in pediatric cancer patients. For this, a two-year retrospective study will be carried out to determine the incidence of adverse effects related to acupuncture and the use of intracutaneous needles in the patient in active treatment and survivor.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Safety of Acupuncture Using Semi-Permanent Needles in a Pediatric Cancer Unit: A Retrospective Study.
    Martínez García E, Jordan I, Nishishinya Aquino MB, López de San Roman Fernández C, et al · · 2026 · PMID 42152774 · DOI 10.1177/15347354261439141

Verify or expand the search:

Other trials of acupuncture

Trials testing the same drug.

Other Fundació Sant Joan de Déu trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05585463.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing